

Operational Summary

for the Nine Months Ended December 31, 2017

February 6, 2018

Mitsubishi Chemical Holdings Corporation

Table of Contents

Consolidated Financial Statements for FY2017 3Q		FY2017 Forecasts	
	Page No.		Page No.
Statements of Operations	4	Statement of Operations	15
Sales Revenue and Core Operating Income by Business Segment	5	Sales Revenue and Core Operating Income by Business Segment	16
Analysis of Core Operating Income	6	References	
Overview of Business Segments	7	Statements of Operations [Quarterly Data]	18
Special Items	11	Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]	19
Cash Flows	12	Business Segment Information	20
Statements of Financial Positions	13		

Mitsubishi Chemical Holdings Corporation has adopted IFRS starting with FY2016 1Q.

List of Abbreviations

FY2017	April 1, 2017 – March 31, 2018	
	1st Quarter (1Q):	April 1, 2017 – June 30, 2017
	2nd Quarter (2Q):	July 1, 2017 – September 30, 2017
	3rd Quarter (3Q):	October 1, 2017 – December 31, 2017
	4th Quarter (4Q):	January 1, 2018 – March 31, 2018
	1st Half (1H):	April 1, 2017 – September 30, 2017
	2nd Half (2H):	October 1, 2017 – March 31, 2018
FY2016	April 1, 2016 – March 31, 2017	
	1st Quarter (1Q):	April 1, 2016 – June 30, 2016
	2nd Quarter (2Q):	July 1, 2016 – September 30, 2016
	3rd Quarter (3Q):	October 1, 2016 – December 31, 2016
	4th Quarter (4Q):	January 1, 2017 – March 31, 2017
	1st Half (1H):	April 1, 2016 – September 30, 2016
	2nd Half (2H):	October 1, 2016 – March 31, 2017
MCHC	Mitsubishi Chemical Holdings Corporation	
MCC	Mitsubishi Chemical Corporation	
MTPC	Mitsubishi Tanabe Pharma Corporation	
LSII	Life Science Institute, Inc.	
TNSC	Taiyo Nippon Sanso Corporation	

Consolidated Statements of Operations

Exchange Rate (¥/\$)	112.7	111.8	111.3	107.3	4.5	4%
Naphtha Price (¥/kl)	44,600	39,900	34,000	32,300	7,600	24%

(Billions of Yen)

	3Q	Nine Months Ended Dec. 31, 2017	3Q	Nine Months Ended Dec. 31, 2016	Change	%	
Continuing Operations	Sales Revenue	957.4	2,762.2	864.3	2,450.6	311.6	13%
	Core Operating Income *	112.7	305.0	93.8	230.1	74.9	33%
	Special Items	(3.8)	(10.8)	(3.5)	(19.7)	8.9	
	Operating Income	108.9	294.2	90.3	210.4	83.8	40%
	Financial Income/Expenses	(1.4)	(6.5)	3.3	(5.2)	(1.3)	
	(Dividend included above)	[1.1]	[4.0]	[1.0]	[3.7]	[0.3]	
	(Foreign Exchange Gain/Loss included above)	[0.2]	[(0.5)]	[5.5]	[0.9]	[(1.4)]	
	Earnings before Taxes	107.5	287.7	93.6	205.2	82.5	
	Income Taxes	(15.0)	(63.9)	(25.6)	(28.0)	(35.9)	
	Net Income from Continuing Operations	92.5	223.8	68.0	177.2	46.6	
Net Income from Discontinued Operations	-	-	2.7	2.6	(2.6)		
Net Income	92.5	223.8	70.7	179.8	44.0		
Net Income Attributable to Owners of the Parent	68.5	169.0	52.6	131.8	37.2	28%	
Net Income Attributable to Non-Controlling Interests	24.0	54.8	18.1	48.0	6.8		

* Equity income included

6.7	18.3	5.4	12.8	5.5
-----	-------------	-----	------	------------

Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring factors (losses incurred by business withdrawal and contraction, etc.).

Sales Revenue and Core Operating Income by Business Segment

(Billions of Yen)

*All figures are approximation for reference purpose only.

		1Q	2Q	3Q	Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
Total Consolidated	Sales Revenue	898.0	906.8	957.4	2,762.2	2,450.6	311.6
	Core Operating Income	95.5	96.8	112.7	305.0	230.1	74.9
Functional Products	Sales Revenue	188.7	195.9	199.7	584.3	553.3	31.0
	Core Operating Income	16.7	16.2	15.4	48.3	49.5	(1.2)
Performance Chemicals	Sales Revenue	88.5	87.6	91.9	268.0	238.3	29.7
	Core Operating Income	9.8	8.1	9.7	27.6	23.8	3.8
Performance Products	Sales Revenue	277.2	283.5	291.6	852.3	791.6	60.7
	Core Operating Income	26.5	24.3	25.1	75.9	73.3	2.6
MMA	Sales Revenue	92.3	92.6	96.7	281.6	208.3	73.3
	Core Operating Income	24.3	27.9	29.2	81.4	26.9	54.5
Petrochemicals	Sales Revenue	127.5	130.9	141.6	400.0	356.7	43.3
	Core Operating Income	5.8	8.7	8.5	23.0	8.4	14.6
Carbon Products	Sales Revenue	68.1	60.2	59.5	187.8	128.6	59.2
	Core Operating Income	4.0	1.2	3.2	8.4	2.0	6.4
Chemicals	Sales Revenue	287.9	283.7	297.8	869.4	693.6	175.8
	Core Operating Income	34.1	37.8	40.9	112.8	37.3	75.5
Industrial Gases	Sales Revenue	149.1	153.1	163.7	465.9	411.0	54.9
	Core Operating Income	13.4	14.7	15.8	43.9	38.9	5.0
Health Care	Sales Revenue	138.1	135.1	155.6	428.8	414.9	13.9
	Core Operating Income	22.0	19.0	31.2	72.2	82.0	(9.8)
Others	Sales Revenue	45.7	51.4	48.7	145.8	139.5	6.3
	Core Operating Income	(0.5)	1.0	(0.3)	0.2	(1.4)	1.6

[Inventory valuation gain/loss]

Performance Chemicals	(0.7)	0.1	1.0	0.4	0.5	(0.1)
Petrochemicals	(1.0)	(0.7)	5.9	4.2	(3.9)	8.1
Carbon products	(0.2)	(0.7)	0.2	(0.7)	0.0	(0.7)
Total	(1.9)	(1.3)	7.1	3.9	(3.4)	7.3


Analysis of Core Operating Income

(Billions of Yen)

	Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change				
				Price	Volume	Fixed Cost	Others *
Total Consolidated	305.0	230.1	74.9	43.3	33.4	11.0	(12.8)
Performance Products	75.9	73.3	2.6	(8.6)	10.8	6.2	(5.8)
Chemicals	112.8	37.3	75.5	51.2	12.1	2.8	9.4
Industrial Gases	43.9	38.9	5.0	0.6	4.7	0.8	(1.1)
Health Care	72.2	82.0	(9.8)	0.1	6.7	1.0	(17.6)
Others	0.2	(1.4)	1.6	0.0	(0.9)	0.2	2.3

* Items included are impacts from inventory valuation gain/loss and Equity Income, etc.

Changes in exchange rates	5.8	6.8	2.1	-	(3.1)
Changes in foreign currency translation included in above		5.9			




Performance Products Segment

		(Billions of Yen)		
		Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
Functional Products	Sales Revenue	584.3	553.3	31.0
	Core Operating Income	48.3	49.5	(1.2)
Performance Chemicals	Sales Revenue	268.0	238.3	29.7
	Core Operating Income	27.6	23.8	3.8
Performance Products	Sales Revenue	852.3	791.6	60.7
	Core Operating Income	75.9	73.3	2.6

Functional Products	
Sales revenue	Sales of advanced moldings and composites including high-performance engineering plastics, alumina fibers, and other products remained firm, and sales remained steady for films for displays in electronics and displays.
Core operating income	Profit decreased due primarily to a rise in raw material costs for high-performance films and films for displays, despite higher sales volumes of high-performance engineering plastics and alumina fibers.
Performance Chemicals	
Sales revenue	In advanced polymers, market prices for phenol-polycarbonate chain continued firm, and sales volumes increased as the impact of scheduled plant maintenance and repairs during the same period of fiscal 2016 was resolved. In addition, sales volumes of battery materials for automobiles in the new energy business increased.
Core operating income	Profit increased, due primarily to higher sales volumes of performance polymers and battery materials for automobiles and epoxy resins, in addition to continued firm market prices of phenol-polycarbonate products.

< Analysis of Core Operating Income >



<Major initiatives>


- MCC decided to invest in C.P.C. SRL, an Italian company manufacturing and selling automobile components made of carbon fiber reinforced plastic in October 2017, as part of its efforts to strengthen the carbon fiber business in the U.S. and European markets. Mitsubishi Chemical Carbon Fiber and Composites GmbH, a wholly owned subsidiary of MCC, acquired a 44% equity stake in CPC from its founder.

Chemicals Segment

(Billions of Yen)

		Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
MMA	Sales Revenue	281.6	208.3	73.3
	Core Operating Income	81.4	26.9	54.5
Petrochemicals	Sales Revenue	400.0	356.7	43.3
	Core Operating Income	23.0	8.4	14.6
Carbon Products	Sales Revenue	187.8	128.6	59.2
	Core Operating Income	8.4	2.0	6.4
Chemicals	Sales Revenue	869.4	693.6	175.8
	Core Operating Income	112.8	37.3	75.5

< Analysis of Core Operating Income >



- MCC's subsidiary, Japan Polypropylene Corporation suspended its polypropylene production line (300kt/y) for four months from the end of September 2017, due to the partially damaged production line. Operation resumed at the end of January 2018.

MMA	
Sales revenue	MMA monomer market prices rose in line with continuing firm demand.
Core operating income	Profit increased due primarily to a broadening in the price differential between raw materials and product in MMA, despite rising raw material prices.
Petrochemicals	
Sales revenue	With continued firmness in the demand and supply balance, sales volumes increased, reflecting rising sales prices brought on by higher raw material prices and a smaller impact from ethylene production facility scheduled maintenance and repairs, which were less than in the previous period.
Core operating income	Profit increased reflecting continued firm market prices for petrochemicals, a smaller impact from ethylene production facility scheduled maintenance and repairs, which were less than in the previous period, and other factors.
Carbon Products	
Sales revenue	Sale prices rose, accompanying a rise in coking coal prices.
Core operating income	Profit increased due primarily to continued steady demand, a broadening in the price differential between raw materials and products, accompanying rising market prices in coke and needle coke.

<Major initiatives>

- The Saudi Methacrylates Company, a joint venture between MCC and Saudi Basic Industries Corporation achieved mechanical completion of production facilities for MMA monomer (250kt/y) and PMMA (40kt/y). Trial operations are currently under way with commercial operations slated to commence in March 2018.
- MCC's subsidiary, Japan Polypropylene Corporation decided to construct a new production facility for polypropylene (150kt/y) at its Goi Plant, as part of its structural reforms in April 2017. Commercial operation is scheduled to begin in October 2019.


Industrial Gases Segment

(Billions of Yen)

		Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
Industrial Gases	Sales Revenue	465.9	411.0	54.9
	Core Operating Income	43.9	38.9	5.0

Industrial Gases	
Sales revenue	Sales revenue increased, reflecting continued firmness in domestic and overseas sales of electronics material gases. Another positive factor was the inclusion of results of businesses acquired in the U.S. and Australia starting in the second quarter and the fourth quarter of fiscal 2016, respectively.
Core operating income	Profit increased, reflecting continued firmness in the domestic industrial gas business such as separate gases, in addition to the effects of the acquisition and firm sales of electronics material gases mentioned above.

< Analysis of Core Operating Income >




Health Care Segment

(Billions of Yen)

		Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
Health Care	Sales Revenue	428.8	414.9	13.9
	Core Operating Income	72.2	82.0	(9.8)

Health Care	
Sales revenue	Pharmaceuticals recorded higher sales revenue, due mainly to sales growth of domestic ethical pharmaceuticals and continued favorable sales of <i>Radicava</i> , a treatment for amyotrophic lateral sclerosis (ALS) in the U.S.
Core operating income	Profit decreased due primarily to increased R&D expenses and business development costs in the U.S., despite sales growth of domestic ethical pharmaceuticals and continued favorable sales of <i>Radicava</i> .

< Analysis of Core Operating Income >



<Major initiatives>

- MTPC's *Radicava*, a free-radical scavenger discovered by Mitsubishi Pharma Corporation (current MTPC) was approved by the U.S. Food and Drug Administration for an indication of ALS in May 2017. Sales of *Radicava* in the U.S. through MTPC's subsidiary, MT Pharma America, Inc. began in August.
- MTPC made NeuroDerm Ltd. a consolidated subsidiary in October 2017. NeuroDerm is a clinical-stage pharmaceutical company that develops novel formulation technology and drug-device combinations for Parkinson's disease.

Consolidated Special Items

					(Billions of Yen)	
	1Q	2Q	3Q	Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Change
Total Special Items	(4.5)	(2.5)	(3.8)	(10.8)	(19.7)	8.9
Impairment loss	(0.0)	(1.1)	(5.0)	(6.1)	(9.8)	3.7
Integration-related expenses of MCC	(2.2)	(0.2)	(0.2)	(2.6)	(0.5)	(2.1)
Special retirement expenses	(1.1)	(0.8)	(0.5)	(2.4)	(2.1)	(0.3)
Loss on sale and disposal of fixed assets	(0.8)	(0.3)	(1.0)	(2.1)	(1.5)	(0.6)
Provision for loss on litigation	-	-	(1.2)	(1.2)	-	(1.2)
Gain on sale of intercompany securities	-	-	3.6	3.6	-	3.6
Gain on sale of property, plant and equipment	0.1	0.1	2.6	2.8	0.7	2.1
Others	(0.5)	(0.2)	(2.1)	(2.8)	* (6.5)	3.7

*Including the impact of losses incurred by the Kumamoto earthquake in Japan (4.0 billion yen)

[Special Items by Business Segment]

Performance Products	(0.3)	(0.2)	(1.6)	(2.1)	* (9.9)	7.8
Chemicals	(0.4)	(0.2)	(2.7)	(3.3)	(7.6)	4.3
Industrial Gases	0.1	(0.1)	0.0	0.0	0.2	(0.2)
Health Care	(0.9)	(2.0)	1.5	(1.4)	(1.0)	(0.4)
Others	(3.0)	(0.0)	(1.0)	(4.0)	(1.4)	(2.6)

Consolidated Cash Flows

	Based on statements of cash flows		Adjusted cash flows*		<reference> Target for FY2017 Forecast (announced on May 12)
	Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	Nine Months Ended Dec. 31, 2017	Nine Months Ended Dec. 31, 2016	
Net cash provided by operating activities	287.2	254.6	287.2	254.6	350.0
Income before income taxes	287.7	207.6	287.7	207.6	277.0
Depreciation and amortization	133.3	129.3	133.3	129.3	182.0
Change in operating receivables/payables	(49.1)	(19.2)	(49.1)	(19.2)	} (44.0)
Change in Inventories	(35.4)	1.6	(35.4)	1.6	
Others	(49.3)	(64.7)	(49.3)	(64.7)	(65.0)
Net cash used in investment activities	(244.3)	(161.3)	(290.4)	(244.5)	(250.0)
Capital expenditure	(167.1)	(149.0)	(167.1)	(149.0)	(249.0)
Sale of assets	27.8	20.4	27.8	20.4	} (1.0)
Investment and loans receivable, etc.	(105.0)	(32.7)	(151.1)	(115.9)	
Free cash flow	42.9	93.3	(3.2)	10.1	100.0
Net cash used in financing activities	(142.8)	(15.1)			
Interest bearing debts	(64.1)	85.5			
Additional acquisition of consolidated subsidiaries' stocks	(2.7)	(48.8)			
Dividends, etc.	(76.0)	(51.8)			
Increase (Decrease) in cash and cash equivalents	(99.9)	78.2			
Effect of exchange rate changes and change in scope of consolidation	7.8	(17.6)			
Cash and cash equivalents at the beginning of the period	363.5	267.1			
Cash and cash equivalents at the end of the period	271.4	327.7			

* Adjusted cash flows based on actual results are calculated by excluding cash flows from investment of surplus funds for explanatory purposes.

Consolidated Statements of Financial Positions

	Dec. 31, 2017	Mar. 31, 2017	Change		Dec. 31, 2017	Mar. 31, 2017	Change
Cash and cash equivalents	271.4	363.5	(92.1)	Interest-bearing debts	1,637.2	1,693.7	(56.5)
Trade receivables	873.0	776.2	96.8	Trade payables	482.9	437.9	45.0
Inventories	581.0	538.1	42.9	Other liabilities	654.5	633.7	20.8
Other current assets	259.1	290.6	(31.5)	Total liabilities	2,774.6	2,765.3	9.3
Total current assets	1,984.5	1,968.4	16.1	Shareholders' equity	1,238.0	1,089.5	148.5
Tangible and Intangible fixed assets	1,694.3	1,658.9	35.4	Other components of equity	39.2	1.9	37.3
Goodwill	430.2	313.0	117.2	Total equity attributable to owners of the parent	1,277.2	1,091.4	185.8
Investment and other non-current assets	583.4	523.2	60.2	Non-controlling interests	640.6	606.8	33.8
Total non-current assets	2,707.9	2,495.1	212.8	Total equity	1,917.8	1,698.2	219.6
Total assets	4,692.4	4,463.5	228.9	Total liabilities and equity	4,692.4	4,463.5	228.9
				Net interest-bearing debts (*)	1,228.4	1,155.9	72.5
				Net D/E ratio	0.96	1.06	(0.10)
				Ratio of equity attributable to owners of the parent to total assets	27.2%	24.5%	2.7%

(Billions of Yen)

* Net interest-bearing debts
 = interest bearing debts (1,637.2 billion yen)
 - {cash and cash equivalents (271.4 billion yen) + investments of surplus funds (137.4 billion yen)}

Consolidated Financial Results Forecasts for FY2017

Consolidated Statements of Operations

Exchange Rate (¥/\$)	111.3	112.7	110.0	111.4	111.3	110.7	0.6
Naphtha Price (¥/kl)	37,600	44,600	48,500	46,600	42,100	40,800	1,300

		1H	3Q	4Q	2H	FY2017	FY2017	Change	% to
		Actual	Actual	Forecast	Forecast	Forecast	Forecast (Announced on Oct 26)		Previous Forecast
Continuing Operations	Sales Revenue	1,804.8	957.4	977.8	1,935.2	3,740.0	3,700.0	40.0	1.1%
	Core Operating Income	192.3	112.7	78.0	190.7	383.0	365.0	18.0	4.9%
	Special Items	(7.0)	(3.8)	(11.2)	(15.0)	(22.0)	(20.0)	(2.0)	
	Operating Income	185.3	108.9	66.8	175.7	361.0	345.0	16.0	4.6%
	Financial Income/Expenses	(5.1)	(1.4)	(5.5)	(6.9)	(12.0)	(12.0)	0.0	
	Earnings before Taxes	180.2	107.5	61.3	168.8	349.0	333.0	16.0	4.8%
	Income Taxes	(48.9)	(15.0)	(19.1)	(34.1)	(83.0)	(93.0)	10.0	
	Net Income from Continuing Operations	131.3	92.5	42.2	134.7	266.0	240.0	26.0	
	Net Income from Discontinued Operations	-	-	-	-	-	-	-	-
Net Income	131.3	92.5	42.2	134.7	266.0	240.0	26.0	10.8%	
Net Income Attributable to Owners of the Parent	100.5	68.5	31.0	99.5	200.0	180.0	20.0	11.1%	
Net Income Attributable to Non-Controlling Interests	30.8	24.0	11.2	35.2	66.0	60.0	6.0		

(Billions of Yen)

Consolidated Sales Revenue and Core Operating Income by Business Segment

* All figures are approximation for reference purpose only.

							(Billions of Yen)		<Reference>
		1H Actual	3Q Actual	4Q Forecast	2H Forecast	FY2017 Forecast	FY2017 Forecast (Announced on Oct 26)	Change	FY2016 Actual (reclassification)
Total Consolidated	Sales Revenue	1,804.8	957.4	977.8	1,935.2	3,740.0	3,700.0	40.0	3,376.1
	Core Operating Income	192.3	112.7	78.0	190.7	383.0	365.0	18.0	307.5
Functional Products	Sales Revenue	384.6	199.7	200.7	400.4	785.0	790.0	(5.0)	744.6
	Core Operating Income	32.9	15.4	14.7	30.1	63.0	65.0	(2.0)	62.2
Performance Chemicals	Sales Revenue	176.1	91.9	97.0	188.9	365.0	360.0	5.0	327.3
	Core Operating Income	17.9	9.7	7.4	17.1	35.0	34.0	1.0	32.0
Performance Products	Sales Revenue	560.7	291.6	297.7	589.3	1,150.0	1,150.0	0.0	1,071.9
	Core Operating Income	50.8	25.1	22.1	47.2	98.0	99.0	(1.0)	94.2
MMA	Sales Revenue	184.9	96.7	108.4	205.1	390.0	380.0	10.0	285.9
	Core Operating Income	52.2	29.2	26.6	55.8	108.0	102.0	6.0	37.9
Petrochemicals	Sales Revenue	258.4	141.6	145.0	286.6	545.0	530.0	15.0	500.3
	Core Operating Income	14.5	8.5	0.5	9.0	23.5	17.0	6.5	20.9
Carbon Products	Sales Revenue	128.3	59.5	67.2	126.7	255.0	255.0	0.0	197.9
	Core Operating Income	5.2	3.2	4.6	7.8	13.0	10.0	3.0	3.8
Chemicals	Sales Revenue	571.6	297.8	320.6	618.4	1,190.0	1,165.0	25.0	984.1
	Core Operating Income	71.9	40.9	31.7	72.6	144.5	129.0	15.5	62.6
Industrial Gases	Sales Revenue	302.2	163.7	159.1	322.8	625.0	610.0	15.0	574.6
	Core Operating Income	28.1	15.8	13.6	29.4	57.5	54.0	3.5	52.1
Health Care	Sales Revenue	273.2	155.6	131.2	286.8	560.0	560.0	0.0	547.0
	Core Operating Income	41.0	31.2	11.8	43.0	84.0	84.0	0.0	98.4
Others	Sales Revenue	97.1	48.7	69.2	117.9	215.0	215.0	0.0	198.5
	Core Operating Income	0.5	(0.3)	(1.2)	(1.5)	(1.0)	(1.0)	0.0	0.2

References

Statements of Operations [Quarterly Data]

Exchange Rate (¥/\$)	107.9	102.9	111.3	112.9	111.4	111.2	112.7
Naphtha Price (¥/kl)	31,600	31,300	34,000	41,800	39,100	36,100	44,600

(Billions of Yen)

		FY2016				FY2017		
		1Q	2Q	3Q	4Q	1Q	2Q	3Q
Continuing Operations	Sales Revenue	794.6	791.7	864.3	925.5	898.0	906.8	957.4
	Core Operating Income *	70.6	65.7	93.8	77.4	95.5	96.8	112.7
	Special Items	(5.6)	(10.6)	(3.5)	(19.2)	(4.5)	(2.5)	(3.8)
	Operating Income	65.0	55.1	90.3	58.2	91.0	94.3	108.9
	Financial Income/Expenses	(5.0)	(3.5)	3.3	(5.1)	(1.4)	(3.7)	(1.4)
	(Dividend included above)	[2.5]	[0.2]	[1.0]	[0.2]	[2.6]	[0.3]	[1.1]
	(Foreign Exchange Gain/Loss included above)	[(3.9)]	[(0.7)]	[5.5]	[(1.4)]	[(0.7)]	[0.0]	[0.2]
	Earnings before Taxes	60.0	51.6	93.6	53.1	89.6	90.6	107.5
	Income Taxes	(19.9)	17.5	(25.6)	(16.4)	(26.3)	(22.6)	(15.0)
Net Income from Continuing Operations	40.1	69.1	68.0	36.7	63.3	68.0	92.5	
Net Income from Discontinued Operations	1.1	(1.2)	2.7	(0.0)	-	-	-	
Net Income	41.2	67.9	70.7	36.7	63.3	68.0	92.5	
	Net Income Attributable to Owners of the Parent	26.1	53.1	52.6	24.5	47.7	52.8	68.5
	Net Income Attributable to Non-Controlling Interests	15.1	14.8	18.1	12.2	15.6	15.2	24.0

* Equity income included

4.0 3.4 5.4 6.1

5.6 6.0

6.7¹⁸

Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]

(Billions of Yen)

*All figures are approximation for reference purpose only.

		FY2016				FY2017		
		1Q	2Q	3Q	4Q	1Q	2Q	3Q
Total Consolidated	Sales Revenue	794.6	791.7	864.3	925.5	898.0	906.8	957.4
	Core Operating Income	70.6	65.7	93.8	77.4	95.5	96.8	112.7
Functional Products	Sales Revenue	182.0	183.6	187.7	192.0	188.7	195.9	199.7
	Core Operating Income	16.1	16.1	17.3	12.8	16.7	16.2	15.4
Performance Chemicals	Sales Revenue	80.0	78.5	79.8	89.0	88.5	87.6	91.9
	Core Operating Income	8.2	6.6	9.0	8.1	9.8	8.1	9.7
Performance Products	Sales Revenue	262.0	262.1	267.5	281.0	277.2	283.5	291.6
	Core Operating Income	24.3	22.7	26.3	20.9	26.5	24.3	25.1
MMA	Sales Revenue	68.9	67.2	72.2	77.6	92.3	92.6	96.7
	Core Operating Income	6.7	9.1	11.1	11.0	24.3	27.9	29.2
Petrochemicals	Sales Revenue	113.1	110.4	133.2	143.6	127.5	130.9	141.6
	Core Operating Income	0.4	(0.2)	8.2	12.5	5.8	8.7	8.5
Carbon Products	Sales Revenue	39.7	42.6	46.3	69.3	68.1	60.2	59.5
	Core Operating Income	(0.1)	0.7	1.4	1.8	4.0	1.2	3.2
Chemicals	Sales Revenue	221.7	220.2	251.7	290.5	287.9	283.7	297.8
	Core Operating Income	7.0	9.6	20.7	25.3	34.1	37.8	40.9
Industrial Gases	Sales Revenue	131.7	133.8	145.5	163.6	149.1	153.1	163.7
	Core Operating Income	11.5	12.9	14.5	13.2	13.4	14.7	15.8
Health Care	Sales Revenue	134.9	128.5	151.5	132.1	138.1	135.1	155.6
	Core Operating Income	29.1	19.9	33.0	16.4	22.0	19.0	31.2
Others	Sales Revenue	44.3	47.1	48.1	58.3	45.7	51.4	48.7
	Core Operating Income	(1.3)	0.6	(0.7)	1.6	(0.5)	1.0	(0.3)

Business Segment Information

Business Domain	Business Segment	Business Sub-Segment		
			Businesses	
Performance Products	Performance Products	Functional Products	Electronics and Displays	Optical films, Electronics and displays, Acetyl
			High Performance Films	Packaging films, Industrial films
			Environment and Living Solutions	Aqua and separator solutions, Infrastructure solutions and agricultural materials
			Advanced Moldings and Composites	High performance engineering plastics, Fibers and textile, Carbon fiber and composite materials, Functional moldings and composites, Almina fiber and light metal products
		Performance Chemicals	Advanced Polymers	Performance polymers, Engineering polymers, Sustainable resources
			High Performance Chemicals	Performance chemicals, Performance materials, Food ingredients
			New Energy	Lithium ion battery materials, Energy transduction device materials
Industrial Materials	Chemicals	MMA	MMA	MMA
		Petrochemicals	Petrochemicals	Basic petrochemicals, Polyolefins, Basic chemical derivatives
		Carbon Products	Carbon	Carbon
	Industrial Gases		Industrial gases	
Health Care	Health Care			Pharmaceuticals
				Life science

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.